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Background: The use of flexible endoscopes is growing rapidly around the world. Domi-
nant approaches to high-level disinfection among resource-constrained countries include
fully manual cleaning and disinfection and the use of automated endoscope reprocessors
(AERs). Suboptimal reprocessing at any step can potentially lead to contamination, with
consequences to patients and healthcare systems.
Aim: To compare the potential results of guideline-recommended AERs to manual disin-
fection along three dimensions e productivity, need for endoscope repair, and infection
transmission risk in India, China, and Russia.
Methods: Financial modelling using data from peer-reviewed published literature and
country-specific market research.
Findings: In countries where revenue can be gained through productivity improvements,
conversion to automated reprocessing has a positive direct impact on financial perfor-
mance, paying back the capital investment within 14 months in China and seven months in
Russia. In India, AER-generated savings and revenue offset nearly all of the additional
operating costs needed to support automated reprocessing.
Conclusion: Among endoscopy facilities in India and China, current survey-reported prac-
tices in endoscope reprocessing using manual soaking may place patients at risk of exposure
to pathogens leading to infections. Conversion from manual soak to use of AERs, as recom-
mendedby theWorldGastroenterologyOrganization,may generate cost and revenueoffsets
that could produce direct financial gains for some endoscopy units in Russia and China.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the Healthcare Infection
Society. All rights reserved.Introduction
The use of flexible endoscopes is growing rapidly around
the world. These costly and delicate instruments must bee CC BY-NC-ND license
-nd/3.0/).
ana Avenue, La Canada,
.com (N.L. Reaven).
uthors. Published by Elsevierreprocessed following each procedure to achieve high-level
disinfection, ensuring that patients are not exposed to a pre-
vious patient’s pathogens. There are no reported cases of
endoscope-transmitted infection in which endoscope reproc-
essing was performed in accordance with professional and
manufacturers’ guidelines.
Missing or rushing through key steps is a common problem in
both industrialized and developing countries. Contaminated
endoscopes have been linked to more outbreaks of hospital-
acquired infection than any other medical device.1Ltd on behalf of the Healthcare Infection Society. All rights reserved.
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at any stage of the process. Inadequate cleaning can leave
excess bio-material on an endoscope, even after multiple
reprocessings.2 In one study of endoscope cleaning practices,
22% of endoscopes still had infective viruses present after
disinfection.3 If the endoscope is not soaked in high-level
disinfectant for a sufficient period of time, hard-to-kill patho-
gens such as bacterial spores, mycobacteria, fungi, Staphylo-
coccus aureus, and viruses such as human immunodeficiency
virus (HIV) and hepatitis B (HBV) may survive.4 If the disinfectant
solution is not thoroughly rinsed from the scope after soaking,
patients can experience the acute discomfort of chemical coli-
tis.5,6 Rutala et al. found that residual glutaraldehyde levels
were up to 25 times higher after manual cleaning compared with
automated disinfection.1
In many countries, the predominant approach to endoscope
reprocessing is a fully manual process (manual soak) in which
the disinfection step involves soaking in glutaraldehyde. Vari-
ability in manual reprocessing has been associated with sub-
optimal results. The World Gastroenterology Organisation
(WGO) recommends the use of an automatic endoscope
reprocessor (AER) where sufficient resources are available, as
the most extensive of a cascade of options for improvement.4
However, in resource-limited countries, assessment of WGO
recommendations requires a thorough understanding of asso-
ciated capital and operating costs compared against quality
improvements and other possible benefits. Accordingly, we
sought to model the financial impact of converting frommanual
soak in GA to an AER, exemplified by the Endoclens-NSX
(Advanced Sterilization Products, Irvine, CA, USA), an AER us-
ing orthophthalaldehyde (OPA), in endoscopy facilities in
Russia, India, and China. An estimate of the potential exposure
to infection under practices reported by endoscopy personnel
in these countries was calculated.Methods
Sources for this analysis include professional standards, espe-
cially those of the WGO; clinical literature accessed through
searches on Medline and Embase; standards and source docu-
mentation of the US Centers for Disease Control and Prevention
(CDC); internet searches for country-specific data in English;
questionnaires and inquiries of field staff; and results of ASP-
funded market research by Junicon (San Ramon, CA, USA). The
market research consisted of 50 minute interviews conducted in
2010 with hospital endoscopy laboratories (25 per country),
sampled with quotas for hospital size and reprocessing method.7
Our analysis compares potential effects of changing from
manual soaking in glutaraldehyde to an AER along three di-
mensions: productivity (including both revenue gain and labour
savings), endoscope repair (including direct repair cost and
revenue gain), and infection rates (number of patients poten-
tially exposed under current practices and implications for
national health systems).
Endoscope reprocessing using manual soak in glutaralde-
hyde requires six main steps: (1) bedside pre-cleaning, (2)
cleaning and brushing, (3) rinsing, (4) soaking in glutaralde-
hyde, (5) final rinsing, and (6) drying with air and/or alcohol.4
Time spent on these steps was estimated separately for each
country from research results. Survey respondents performing
manual soak processes in each target country were asked forthe number of minutes from the end of one procedure until the
scope is ready for the next patient (total scope turnaround
time). Subtracting the average soaking time in glutaraldehyde,
reported on the same survey, provided the minutes available
for all other reprocessing tasks, from which a minimal allow-
ance of 3.4 min, calculated from literature sources, was allo-
cated for final rinsing/drying.8
With an AER, the soaking, final rinsing and drying steps are
all done in the machine, which also performs supplemental
cleaning and rinsing of the scope. The manufacturer-rec-
ommended soaking time for OPA in an AER unit is five min,
versus the WGO-recommended 20 min soak in glutaraldehyde
with manual reprocessing. The same first three steps are
performed in both processes; our estimates assume that
personnel will perform those tasks at current levels of time
and diligence with or without an AER. The manufacturer-
specified cycle time of 19 min for Endoclens-NSX was
assumed for the AER.
The productivity impact of an AER was estimated using
an operational model that compared average endoscopy
procedure time (plus a one min allowance for moving pa-
tients) to the operational flow of scope reprocessing under
both systems. Endoscopy procedure time was estimated us-
ing the survey-reported mix of endoscopy procedure types in
each country and procedure times reported in the literature
(22 min for colonoscopy and 36 min for bronchoscopy) or by
Medicare (20 min for gastroscopy).2,9 We assumed a simpli-
fied model of two primary working scopes per procedure
room e meaning that a scope from one patient procedure is
reprocessed while a second patient procedure is performed;
delays occur if the first scope is not ready by completion of
the second procedure. The value of reducing these delays is
realized by adding procedures to the daily schedule, poten-
tially increasing revenues.Results
Productivity
Average survey-reported scope turnaround time under
manual soak ranged from 21.5 min in India to 47.5 min in Russia
(Table I).7 In India, where scope turnaround under manual soak
(21.5 min) is less than estimated endoscopy procedure time
(22.6 min), no systematic delay occurs; AER adoption yields no
additional procedures or revenue gain. In Russia, scope turn-
around time (47.5 min) is significantly longer than the average
endoscopy procedure (24.4 min). In China, scope turnaround
time is slightly longer than the average procedure time (26.2
vs 22.3 min), resulting in an average per-procedure delay of
2.5 min.
Scope turnaround time using an AER with OPA is faster than
with manual soak. The resulting reduction in procedure room
delays means that an average of 3.9 procedures could be added
per day in Russia (3.9 min per procedure reduction in
delay  24.5 procedures per day/24.4 min per procedure),
resulting in an annual revenue gain of (US)$47,353 (3.9 pro-
cedures/day  five operational days/week  52 weeks/
year  $47 per procedure).3 Similarly, we estimate revenue
gains of $67,485 in China. Direct labour savings were minimal,
yielding estimated total annual savings of $111, $622, $513 in
India, Russia, and China, respectively.
Table I
Survey-reported average total turnaround time per endoscope and soak time by country, and estimated allocation of time among
reprocessing tasks based on survey-reported soak time and studies
Variable Reprocessing time (min)
India Russia China
Total scope turnaround time, mean (95% CI)a 21.5 (19.7, 23.0) 47.5 (43.5, 51.5) 26.2 (22.0, 30.4)
Soak time in glutaraldehydea 20.0 20.0 20.0
Reprocessing tasks other than soaking
(time available for cleaning, rinsing/drying)
(calculated)
1.5 27.5 6.2
Manual cleaning and rinsing before soaking
(calculated)
0.8 24.1 3.1
Final rinse and dry after soakingb 0.8 3.4 3.1
CI, confidence interval.
a Survey-reported value.
b Value calculated from literature, subject to limitation that time for cleaning, soaking and rinsing cannot exceed total scope turnaround
time.
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The potential to reduce the cost of endoscope repairs with
an AER derives from an estimated 34% reduction in the amount
of manual handling during reprocessing, resulting in fewer
opportunities for the scope to be inadvertently mishandled.
From a survey of 43 centres, Kirkpatrick et al. found that 18% of
endoscope damage occurs during reprocessing.10 We estimated
savings in repair costs at 34%  18%  the facility’s annual cost
of preventable repairs, which studies indicate are 58% more
costly than unavoidable repairs.11,12 Individual repairs vary
widely in cost, depending on the nature of the damage,
whereas field personnel consistently reported an average cost
per repair of $5,000. With literature indicating that 64% of
endoscope repairs are preventable, we estimated that pre-
ventable repairs (58% more costly) would average $5,763,
whereas unavoidable ones would average $3,643.5 Estimated
annual repair costs under current manual soak also considered
the mix of procedures and the literature-reported average
number of uses between repairs (94.5 to 98.4 uses per repair)
for bronchoscopes and other endoscopes.5e7
Additionally, when a scope is sent out for unplanned repairs,
procedures may have to be cancelled. We assumed five days
per unplanned repair (at five procedures per day) until other
patients could be scheduled for procedures using a different
type of scope or a loaned scope. Thus, assuming an average
revenue of $47 per procedure, the average annual gain in
revenue expected to result from a reduction in avoidable
endoscope repairs was $2,772 in India (2.4 repairs avoided per
year), $4,101 in Russia (3.5 repairs), and $8,649 in China (7.4
repairs).Infection exposure risk
The WGO recommends the use of AERs, which supplement
manual cleaning with additional washing and rinsing to reduce
the risk of disease transmission via endoscopes.2 Since the risk
of transmitting disease via a poorly cleaned endoscope cannot
be studied prospectively in humans, we relied on an animal
study. In a study used by the US CDC to establish endoscope
reprocessing standards, endoscopes used on HBV-infectedducks were soaked in glutaraldehyde for 5, 10, and 20 min,
with no prior manual cleaning.13 Healthy ducks were injected
with material from the soaked but uncleaned endoscopes,
resulting in HBV infection rates of 90%, 70%, and 6%, respec-
tively; suggesting that the 20 min glutaraldehyde soak re-
ported by most surveyed endoscopy centres could leave
transmissible viruses on 6% of scopes if no cleaning was per-
formed first.
When all recommended reprocessing standards are fol-
lowed, the risk of disease transmission from an endoscope is
virtually non-existent e all reported cases have been associ-
ated with a breach of these protocols or defective equip-
ment.14 Alfa et al. reported that well-trained personnel
performing manual cleaning in accordance with manufac-
turers’ recommendations and professional standards required
14min (bronchoscopes) to 25 min (side-viewing duodeno-
scopes) for the cleaning tasks; we assumed a mid-point of 19
min as the time required for the manual cleaning portion of
reprocessing.15 We are aware of no systematic observational
study of actual endoscope reprocessing practices in India,
China, and Russia. Accordingly, we estimated manual cleaning
time in these countries using survey-reported average scope
turnaround and soaking times (Table I). For the final rinse and
dry, we allowed a conservative 3.4 min, consistent with
observed practice in a study by Ofstead et al. that did not
assess the adequacy of the rinsing performed.4 We compared
the remaining minutes, assumed to be spent in manual clean-
ing, to the 19 min time for cleaning to professional standards,
in order to estimate the percentage of required cleaning
actually performed. Estimated manual cleaning times in India
(0.8 min) and China (3.1 min), as a percentage of optimal
cleaning efforts were 4% in India, 16% in China, and 123% in
Russia. Total endoscope turnaround time in Russia (an average
of 47.5 min) allows enough time for manual cleaning to pro-
fessional standards, especially if performed by experienced
personnel.
As previously noted, studies have shown that no scopes
soaked for 20 min in glutaraldehyde after being fully cleaned to
professional standards, and 6% of scopes not cleaned at all,
retain transmissible pathogens. We assumed a linear relation-
ship between the percentage of optimal cleaning effort and the
amount of this remaining risk eliminated. Thus, as shown in
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Figure 1. Endoscope cleaning effort and estimated proportion of
endoscopes that could still retain transmissible pathogen. [ ], %
scopes on which pathogen, if present, could remain after
reprocessing (left axis); [ ], minutes of manual cleaning per scope
(right axis). Time needed for cleaning to standard: 19 min.
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soak reprocessing, 4.3% of reprocessed endoscopes in China
and 5.6% in India could still retain transmissible pathogens.
Furthermore, pathogens may be present on a poorly cleaned
scope only if a prior patient was infected. Accordingly, the
absolute risk of an endoscopy patient being exposed to a
pathogen was estimated for India and China for three viral
diseases (all of which can be transmitted by endoscope) as theTable II
Estimated number of endoscopy patients exposed to HBV, HCV and
HIV in three countries, based on self-reported practices for
reprocessing using manual soak in glutaraldehyde and country-
specific ranges of disease prevalence
Variable India Russia China
Annual procedure volume per
GI unit
3840 5880 11,904
Estimated % of infected scopes
retaining transmissible
pathogens
5.6% 0 4.3%
Disease prevalence
HBV e low 2.0% 2.0% 8.0%
HBV e high 10.0% 7.0% 20.0%
HCV 1.3% 2.0% 3.2%
HIV 0.3% 1.0% 0.1%
% of manually reprocessed
scopes estimated to retain
viable pathogen
HBV e low 0.11% 0 0.35%
HBV e high 0.56% 0 0.87%
HCV 0.07% 0 0.14%
HIV 0.02% 0 0
Potential number of patients
exposed annually in an
average GI unit under current
reprocessing practices
HBV e low 4 e 41
HBV e high 21 e 103
HCV 3 e 17
HIV 1 e 1
HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immuno-
deficiency virus; GI, gastrointestinal.product of the percentage of scopes that could retain trans-
missible pathogens and the societal prevalence of the dis-
ease.16e22 As shown in Table II, we estimate that current
practices in an average endoscopy facility in China could result
in the exposure of between 41 and 103 patients to HBV, 17
patients to hepatitis C (HCV) and one patient to HIV, annually.
If one patient is infected for each incident of disease exposure,
patients survive at least 1e10 years and receive treatment at
an annual cost for HBV of $13 in India and $2 116 in China,21e25
the estimated cumulative national impact over 10 years would
be roughly $25 million in India and $170 billion in China.23e26
Capital investment and operating costs
The cost of acquiring and operating the AER unit must also
be taken into consideration. We assumed a capital investment
per endoscopy facility for the AER(s) and initial service con-
tracts of $22,750 in India, $27,887 in Russia, and $60,000 in
China (two units). The incremental increase in supply costs
with an AER includes all manufacturer-recommended filter
changes, pre-filter (where required), Cidex OPA Solution,
detergent and test strips used per manufacturer standards,
versus manual soak costs based on current reported usage and
estimated product costs. The resulting increase in supply costs
is shown in Table III.Table III
Summary of cost increases, savings and revenue gains (US$) with an
Endoclens-NSX automatic endoscope reprocessor (AER)
compared with manual soak in glutaraldehyde
India Russia China
Added cost of AER supplies
Savings (added cost) on
supplies e fluids, filters
and strips
$(17,141) $(23,216) $(66,808)
Cost savings generated by use of an AER
Repairs. Potential reduction
in cost of repairs
$13,737 $20,319 $42,858
Labour time. Nurse/tech
time savings from reduction
in hands-on tasks
$111 $622 $513
Subtotal: cost savings $13,847 $20,941 $43,371
Revenue gains generated by use of an AER
Repairs. Potential
reduction in frequency
of scopes out for repair
$2,772 $4,101 $8,649
Productivity. Processing
time efficiency gain (loss)
e $47,353 $67,485
Subtotal: revenue increase
(decrease)
$2,772 $51,453 $76,135
Subtotal: cost savings and
revenue enhancements
$16,620 $72,394 $119,506
Total: grand total change in
annual operating margin
$(522) $49,179 $52,698
Capital investment: AER
unit(s) þ initial service
contract
$22,750 $27,887 $60,000
Payback period (years) NA 0.57 1.14
Payback period (months) 7 14
NA, not applicable.
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Estimated annual costs and financial benefits of the AER unit
versus manual soak in glutaraldehyde are summarized in
Table III. In countries where revenue can be gained through
productivity improvements, adopting the AER has positive
direct impact on financial performance, achieving payback of
capital investment within 14 months in China and seven months
in Russia. In India, AER-generated savings and revenue offset
nearly all of the additional operating costs for the AER.
Discussion
This study has several limitations. The results presented
here use country-wide averages, which may not be represen-
tative of individual facilities. Analysis of current practices is
based on self-reported data, and self-reported glutaraldehyde
soaking time of 20 min (as is widely recommended) would leave
little time for cleaning and rinsing if total scope turnaround
barely exceeded 20 min, as was reported. Additionally, im-
munization rates would affect the risk of actual disease
transmission and this has not been accounted for in our esti-
mates. Water quality testing and regular training to ensure
staff competency are recommended for both AER use and
manual reprocessing; differential costs for water and energy
use, staff training, or water quality testing have not been
assessed or included, and may be higher if an AER is adopted.
In developing economies, the decision to invest in capital
equipment is made within a context of limited resources and
competing demands. Assessments of operational costs versus
operational benefits and disease prevention are rarely seen in
the literature, in part due to the paucity of country-specific
comparative data. As a first step in an open assessment of
automated endoscope reprocessing in three emerging econo-
mies, we examined the costs and potential benefits along three
dimensions of efficiency and outcomes. Among endoscopy fa-
cilities in India and China, survey results on endoscope
reprocessing using manual soak suggest practices that are not
in compliance with manufacturer instructions and WGO
guidelines, and could place patients at risk of exposure to in-
fections. Conversion from manual soak to use of an AER as
recommended by the WGO may generate cost and revenue
offsets that could result in direct financial gains for some
endoscopy units in Russia and China.
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